Aeterna Zentaris (AEZS) lands IND FDA approval for the initiation of a Phase 2A trial to assess the firm's treatment for cancer cachexia. The firm says if its AEZS-130 drug is effective, subjects could receive more effective doses of chemotherapy and have a better functional status.
Sent to 3,294 people who get email alerts on AEZS.
Get email alerts on AEZS »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $30.